ClinicalTrials.gg
Not yet recruitingNCT07564323Updated May 4, 2026

Implantation of an Adjustable Suburethral Sling is an Effective Treatment Method for Patients With Mixed Urinary Incontinence of Moderate to Severe Severity, After Which the Severity of the Stress and Urgency Components is Reduced.

An interventional study of implantation of an adjustable suburethral sling in Mixed Urinary Incontinence, sponsored by Saint Petersburg State University, Russia. Not yet recruiting. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-04.

Sponsored by Saint Petersburg State University, Russia · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
156
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Study summary

The aim of this clinical study is to optimize treatment outcomes in patients with mixed forms of urinary incontinence by implanting an adjustable suburethral sling and to determine factors influencing treatment effectiveness. The main questions it aims to answer are:

  1. What is the effectiveness of an adjustable suburethral sling in patients with mixed urinary incontinence?
  2. How do preoperative medications and other factors affect the effectiveness of adjustable suburethral sling implantation?
  3. How does quality of life change in these patients after surgery? Participants will undergo implantation of an adjustable suburethral sling. Postoperatively, the effectiveness of the sling for mixed urinary incontinence will be assessed. Predictors of treatment effectiveness will also be identified.

Patients will be examined 24 hours after surgery, 2 months later, and 1 year later.

02

Conditions studied

  • Mixed Urinary Incontinence

Browse trials for

Keywords

  • mixed urinary incontinence, adjustable suburethral sling
03

In context

Urinary Incontinence

988 studies on the registry are indexed under Urinary Incontinence; 184 are open to participants now.

This study's planned enrollment of 156 is above the median of 66 across 743 interventional studies indexed under Urinary Incontinence.

Browse Urinary Incontinence studies →

Lead sponsor

Saint Petersburg State University, Russia is the lead sponsor of 34 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women over 18 years of age.
  • Mixed urinary incontinence (stress and urgency components, with the stress component being predominant or equal) of moderate to severe severity, confirmed by questionnaire data.
  • Signed to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • Isolated stress or urge urinary incontinence.
  • to diagnosis and treatment.
  • Obstructive urination, large residual urine volume.
  • Chronic pelvic pain syndrome.
  • Pelvic organ prolapse (grade 2 or higher according to POP-Q).
  • History of any suburethral sling implantation.
  • History of surgical treatment for pelvic organ prolapse.
  • Pregnancy.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
156 participants (estimated)

Study arms

  • Experimental
    Patients with mixed urinary incontinence

    Patients with mixed urinary incontinence, who were or were not prescribed drug therapy before the start of the study, planned for surgical treatment - implantation of a suburethral adjustable sling.

    Procedure: implantation of an adjustable suburethral sling

Interventions

  • Procedureimplantation of an adjustable suburethral sling

    Surgical access will be achieved through the anterior vaginal wall, projecting toward the middle third of the urethra. The UroSling endoprosthesis will be inserted using the standard technique.

06

What researchers measure

Primary outcomes

  1. The Overactive Bladder Symptom Score (OABSS) questionnaire

    Changes in scores on the Overactive Bladder Symptom Score (OABSS) questionnaire at 24 hours postoperatively compared to pre-treatment values.

    Time frame: At 24 hours postoperatively compared

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Apr 2027, 12 months later.

Of 303 non-industry interventional studies with no phase under Urinary Incontinence, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 37. This study's planned 12 months is below that.

Counting every sponsor, half of 366 studies reached it within 15 months; a quarter within 7 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2026
First posted
May 4, 2026
StartEst.
Apr 24, 2026
Primary completionEst.
Apr 24, 2027
CompletionEst.
Apr 24, 2028
Last update
May 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07564323
Lead sponsor
Saint Petersburg State University, Russia
Responsible party
Brednikhina Irina (Urologist, Saint Petersburg State University, Russia) — Principal investigator
First posted
May 4, 2026
Start date
Apr 24, 2026 (estimated)
Primary completion
Apr 24, 2027 (estimated)
Completion
Apr 24, 2028 (estimated)
Last update
May 4, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion